KKKrishna Kumar

Krishna Kumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Krishna Kumar has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Stabilizing Full-Length PYY for Native Y1R/Y2R Dual Agonism

    by Marina V. Spenciner, Tristan C. Dinsmore, Vittorio Montanari, Martin Beinborn, Krishna Kumar

    Peptide agonists that engage multiple G protein-coupled receptors provide a framework for orchestrating discrete but complementary signaling pathways within a single molecular entity. Peptide YY (PYY) is an endogenous 36-residue multiagonist of the neuropeptide Y receptor (YR) family. Full-length PYY(1–36) activates both Y1R and Y2R, coupling Y1R-dependent pancreatic and glucoregulatory signaling with Y2R-dependent satiety pathways. This native dual agonism is rapidly uncoupled by the ubiquitous dipeptidyl peptidase-4 (DPP4), which removes the N-terminal dipeptide to yield PYY(3–36), a Y2R-selective ligand with markedly reduced Y1R activity. Thus, DPP4 hydrolysis alters the receptor pharmacology of PYY rather than merely shortening peptide lifetime. Here, we report chemically stabilized PYY analogues that are refractory to DPP4 while retaining potent agonism at both Y1R and Y2R. Preservation of this native dual agonism was not achieved by introducing 2-aminoisobutyric acid (Aib) at the penultimate N-terminal residue. Although Aib is widely used to protect GLP-1 and GIP receptor agonists from DPP4, it results in PYY derivatives with diminished receptor activity at the Y1R. N-terminal alkylation afforded a minimally perturbative strategy to block DPP4 recognition while maintaining the full-length PYY(1–36) functional pharmacophore. Structure–activity studies define N-terminal features required for dual-receptor potency and identify a lipidation site that retains receptor activity while producing an HSA-dependent potency shift consistent with albumin association. Together, these protease-stable PYY(1–36) analogues expand the chemical framework for preserving native multireceptor pharmacology in DPP4-sensitive peptides and for engineering long-acting therapeutic analogues.

  • Amping Up Receptor Balance and Bias: Fine Tuning of Unimolecular Multiagonists

    by Damla Sürmeli, Kathleen M. Sicinski, Tristan C. Dinsmore, Venkata S. Raman, Vittorio Montanari, Martin Beinborn, Krishna Kumar

    Unimolecular multiagonists integrating GLP-1R/GIPR, and increasingly GCGR agonism, have altered the landscape of peptide therapeutics for metabolic syndrome. This progress has shifted the field from optimizing individual ligands to engineering defined receptor selectivity (balance) and, in some cases, pathway-selective signaling (bias) within a single-peptide scaffold. Despite this momentum, tuning ‘balance’ and ‘bias’ remains difficult because small sequence changes can have receptor-dependent, nonintuitive effects, and meaningful retuning often requires wholesale scaffold redesign. Here, we implement a systematic strategy based on simple N-terminal chemical modifications across dual- and triagonist templates to decouple these variables. Because the peptide N-terminus is buried within the membrane-embedded transmembrane core of class B GPCRs, localized chemical edits at this site provide a sensitive lever for reweighting receptor activation. These minimal changes can alter signaling preference without loss of efficacy, expanding the design grammar and offer rapid tuning of potency, efficacy, and bias.

  • Molecular Design of Unimolecular Tetra-Receptor Agonists

    by Tristan C. Dinsmore, Jacob E. Cortigiano, Siyuan Xiang, Marina V. Spenciner, Alexandra R. Dobbins, Richard L. Zhao, Brett M. Waldman, Martin Beinborn, Krishna Kumar

    Peptide hormone-receptor interactions serve as critical regulators of metabolic homeostasis, a paradigm exemplified by the clinical efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists. Building upon this framework, strategic design has yielded unimolecular dual and triple agonists targeting GLP-1R, glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GcgR), leveraging the sequence homology within the cognate native ligands of the class B G protein-coupled receptor (GPCR) family. However, the integration of Y2 receptor (Y2R) agonism─engaged by peptide YY (PYY) and belonging to the structurally divergent class A GPCR family─has remained an unaddressed challenge due to the topological and sequence disparities between these receptor classes. Y2R activation plays a pivotal role in appetite suppression, potentiating the metabolic benefits conferred by GLP-1R, GIPR, and GcgR agonism. Here, we report first-in-class, unprecedented tetra-agonists with high potency at GLP-1R, GIPR, GcgR, and Y2R. The chimeric peptides overcome the intrinsic sequence constraints imposed by class A and class B GPCR divergence, demonstrating the feasibility of rationally designed agonism mediated by single agents across receptor families. Lipidation of this template is well tolerated enhancing the promise of therapeutic viability. Furthermore, we show that biased agonism at GLP-1R selectively boosts cyclic AMP (cAMP) signaling while minimizing β-arrestin recruitment, thereby decoupling receptor desensitization from metabolic efficacy. Additionally, we introduce a tunable framework to modulate β-arrestin engagement without compromising cAMP potency, providing insight into the fine-tuning of GPCR-mediated signaling for next-generation peptide therapeutics.


  • Potent and Protease Resistant Azapeptide Agonists of the GLP‐1 and GIP Receptors

    by Tristan C. Dinsmore, Jamie Liu, Jiayuan Miao, Özge Ünsal, Damla Sürmeli, Martin Beinborn, Yu‐Shan Lin, Krishna Kumar

    The gut‐derived peptide hormones glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) play important physiological roles including glucose homeostasis and appetite suppression. Stabilized agonists of the GLP‐1 receptor (GLP‐1R) and dual agonists of GLP‐1R and GIP receptor (GIPR) for the management of type 2 diabetes and obesity have generated widespread enthusiasm and have become blockbuster drugs. These therapeutics are refractory to the action of dipeptidyl peptidase‐4 (DPP4), that catalyzes rapid removal of the two N‐terminal residues of the native peptides, in turn severely diminishing their activity profiles. Here we report that a single atom change from carbon to nitrogen in the backbone of the entire peptide makes them refractory to DPP4 action while still retaining full potency and efficacy at their respective receptors. This was accomplished by use of aza‐amino acids, that are bioisosteric replacements for α‐amino acids that perturb the structural backbone and local side chain conformations. Molecular dynamics simulations reveal that aza‐amino acid can populate the same conformational space that GLP‐1 adopts when bound to the GLP‐1R. The insertion of an aza‐amino acid at the second position from the N‐terminus in semaglutide and in a dual agonist of GLP‐1R and GIPR further demonstrates its capability as a viable alternative to current DPP4 resistance strategies while offering additional structural variation that may influence downstream signaling.


  • Potent and Protease Resistant Azapeptide Agonists of the GLP‐1 and GIP Receptors

    by Tristan C. Dinsmore, Jamie Liu, Jiayuan Miao, Özge Ünsal, Damla Sürmeli, Martin Beinborn, Yu‐Shan Lin, Krishna Kumar

    The gut‐derived peptide hormones glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) play important physiological roles including glucose homeostasis and appetite suppression. Stabilized agonists of the GLP‐1 receptor (GLP‐1R) and dual agonists of GLP‐1R and GIP receptor (GIPR) for the management of type 2 diabetes and obesity have generated widespread enthusiasm and have become blockbuster drugs. These therapeutics are refractory to the action of dipeptidyl peptidase‐4 (DPP4), that catalyzes rapid removal of the two N‐terminal residues of the native peptides, in turn severely diminishing their activity profiles. Here we report that a single atom change from carbon to nitrogen in the backbone of the entire peptide makes them refractory to DPP4 action while still retaining full potency and efficacy at their respective receptors. This was accomplished by use of aza‐amino acids, that are bioisosteric replacements for α‐amino acids that perturb the structural backbone and local side chain conformations. Molecular dynamics simulations reveal that aza‐amino acid can populate the same conformational space that GLP‐1 adopts when bound to the GLP‐1R. The insertion of an aza‐amino acid at the second position from the N‐terminus in semaglutide and in a dual agonist of GLP‐1R and GIPR further demonstrates its capability as a viable alternative to current DPP4 resistance strategies while offering additional structural variation that may influence downstream signaling.

  • Prolonged Activation of the GLP-1 Receptor via Covalent Capture

    by Özge Ünsal, Z. Selin Bacaksiz, Vladislav Khamraev, Vittorio Montanari, Martin Beinborn, Krishna Kumar

    The incretin gut hormone glucagon-like peptide-1 (GLP-1) has become a household name because of its ability to induce glucose-dependent insulin release with accompanying weight loss in patients. Indeed, derivatives of the peptide exert numerous pleiotropic actions that favorably affect other metabolic functions, and consequently, such compounds are being considered as treatments for a variety of ailments. The ability of native GLP-1 to function as a clinical drug is severely limited because of its short half-life in vivo. All of the beneficial effects of GLP-1 come from its agonism at the cognate receptor, GLP-1R. In our quest for long-lived activation of the receptor, we hypothesized that an agonist that had the ability to covalently cross-link with GLP-1R would prove useful. We here report the structure-guided design of peptide analogues containing an electrophilic warhead that could be covalently captured by a resident native nucleophile on the receptor. The compounds were evaluated using washout experiments, and resistance to such washing serves as an index of prolonged activation and covalent capture, which we use to tabulate longevity and robust long-lived GLP-1R agonism. The addition of SulF (cross-linkable warhead), an N-terminal trifluoroethyl group (for protease protection), and a C18 diacid lipid (protractor) all contributed to the increased wash resistance of GLP-1. The most effective compound based on the wash resistance metric, C2K26DAC18_K34SulF, has all three elements outlined and may serve as a blueprint and a proof-of-concept scaffold for the design of clinically useful molecules.


  • Molecular design of peptide therapeutics via N-terminal modification

    by Damla Sürmeli, Tristan C Dinsmore, Haley M Anchukaitis, Vittorio Montanari, Martin Beinborn, Krishna Kumar


  • A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP Analogues

    by Kathleen M. Sicinski, Damla Sürmeli, Jasper Du, Venkata S. Raman, Vittorio Montanari, Minhee Lee, Benjamin N. Harwood, Alan S. Kopin, Martin Beinborn, Krishna Kumar

    Glucose-dependent insulinotropic peptide (GIP) is a 42-amino acid peptide hormone that regulates postprandial glucose levels. GIP binds to its cognate receptor, GIPR, and mediates metabolic physiology by improved insulin sensitivity, β-cell proliferation, increased energy consumption, and stimulated glucagon secretion. Dipeptidyl peptidase-4 (DPP4) catalyzes the rapid inactivation of GIP within 6 min in vivo. Here, we report a molecular platform for the design of GIP analogues that are refractory to DPP4 action and exhibit differential activation of the receptor, thus offering potentially hundreds of GIP-based compounds to fine-tune pharmacology. The lead compound from our studies, which harbored a combination of N-terminal alkylation and side-chain lipidation, was equipotent and retained full efficacy at GIPR as the native peptide, while being completely refractory toward DPP4, and was resistant to trypsin. The GIP analogue identified from these studies was further evaluated in vivo and is one of the longest-acting GIPR agonists to date.


  • Front Cover: Towards Non‐stick Silk: Tuning the Hydrophobicity of Silk Fibroin Protein (ChemBioChem 22/2022)

    by Julia N. Fountain, Morgan J. Hawker, Lauren Hartle, Junqi Wu, Vittorio Montanari, Jugal Kishore Sahoo, Luke M. Davis, David L. Kaplan, Krishna Kumar

  • Towards Non‐stick Silk: Tuning the Hydrophobicity of Silk Fibroin Protein

    by Julia N. Fountain, Morgan J. Hawker, Lauren Hartle, Junqi Wu, Vittorio Montanari, Jugal Kishore Sahoo, Luke M. Davis, David L. Kaplan, Krishna Kumar

    Silk fibroin protein is a biomaterial with excellent biocompatibility and low immunogenicity. These properties have catapulted the material as a leader for extensive use in stents, catheters, and wound dressings. Modulation of hydrophobicity of silk fibroin protein to further expand the scope and utility however has been elusive. We report that installing perfluorocarbon chains on the surface of silk fibroin transforms this water‐soluble protein into a remarkably hydrophobic polymer that can be solvent‐cast. A clear relationship emerged between fluorine content of the modified silk and film hydrophobicity. Water contact angles of the most decorated silk fibroin protein exceeded that of Teflon®. We further show that water uptake in prefabricated silk bars is dramatically reduced, extending their lifetimes, and maintaining mechanical integrity. These results highlight the power of chemistry under moderate conditions to install unnatural groups onto the silk fibroin surface and will enable further exploration into applications of this versatile biomaterial.